CagriSema vs P21
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CagriSema
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide, developed by Novo Nordisk. By combining two distinct appetite-regulating peptide hormones, CagriSema aims to achieve greater weight loss than semaglutide alone. Phase 3 data showed 22.7% body weight reduction, and an FDA response is expected in 2026.
Full details →P21
P21 is a synthetic peptide derived from Cerebrolysin, specifically designed to mimic the neurotrophic effects of the parent compound. It promotes neurogenesis and has shown cognitive-enhancing properties in research.
Full details →Side-by-Side Comparison
| Aspect | CagriSema | P21 |
|---|---|---|
| Mechanism | CagriSema combines two complementary peptide mechanisms: (1) Semaglutide — GLP-1 receptor agonist providing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic appetite suppression. (2) Cagrilintide — a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus, providing additional appetite suppression via a distinct neuronal pathway from GLP-1. The combination produces additive weight loss by engaging two independent satiety signaling systems. | Inhibits glycogen synthase kinase-3β (GSK-3β) and activates CREB signaling pathway. This promotes BDNF expression, neurogenesis in the hippocampus, and synaptic plasticity. |
| Typical Dosage | Phase 3 trial doses: cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (fixed combination in a single injection). Dose escalation: start at cagrilintide 0.15 mg / semaglutide 0.25 mg weekly and escalate over 16 weeks to the maintenance dose. Administered as a single injection combining both peptides. | Research protocols typically use 1-5mg administered intranasally or subcutaneously. Often used in cycles of 2-4 weeks. |
| Administration | Single subcutaneous injection once weekly, combining both peptides. Pre-filled pen device. Not yet commercially available. FDA response expected 2026. | Can be administered intranasally for direct CNS access or subcutaneously. Best used cyclically rather than continuously. |
| Side Effects | Phase 3 data: nausea, vomiting, diarrhea, constipation (similar profile to semaglutide alone, but some reports suggest modestly higher GI rates). Decreased appetite. Injection site reactions. | Limited data. Reported effects include mild headache, temporary brain fog during initial use, and fatigue. |
| Best For |
Key Differences
Unique to CagriSema:
Unique to P21:
Detailed Analysis
Commonalities
CagriSema and P21 are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose CagriSema for Weight Loss, Diabetes Management. Choose P21 for Cognitive Performance.
Ready to Learn More?
Looking for trusted sources?